“Non-alcoholic Fatty Liver Disease (NAFLD) Pipeline Insight, 2023” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the Non-alcoholic Fatty Liver Disease Market.
The Non-alcoholic Fatty Liver Disease Pipeline report embraces in-depth commercial, regulatory, and Non-alcoholic Fatty Liver Disease clinical trial assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the emerging Non-alcoholic Fatty Liver Disease drugs, including the mechanism of action, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.
Non-alcoholic Fatty Liver Disease (NAFLD) Pipeline Analysis
The report provides insights into:
The report provides detailed insights into the emerging therapies for Non-alcoholic Fatty Liver Disease treatment and the aggregate therapies developed by major pharma companies.
It accesses the different Non-alcoholic Fatty Liver Disease therapies segmented into early-stage, mid-stage, and late-stage of clinical development.
It outlines the major Non-alcoholic Fatty Liver Disease companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
The report evaluates the Non-alcoholic Fatty Liver Disease drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Non-alcoholic Fatty Liver Disease therapeutic market.
Analysis of Emerging Non-alcoholic Fatty Liver Disease Therapies by Phases
The report covers the emerging products under different phases of clinical development like –
Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Learn How the Non-alcoholic Fatty Liver Disease Treatment Outlook will Evolve with the Ongoing Clinical & Commercial Activities in the Therapeutic Market @
https://www.delveinsight.com/sample-request/non-alcoholic-fatty-liver-disease-nafld-pipeline-insight
Non-alcoholic Fatty Liver Disease (NAFLD) Therapeutics Landscape
Several major pharma and biotech companies are developing therapies for Non-Alcoholic Fatty Liver Disease. Currently, Inventiva Pharma is leading the therapeutics market with its Non-Alcoholic Fatty Liver Disease drug candidates in the most advanced stage of clinical development.
On June 12, 2023, Merck (NYSE: MRK) announced that new findings for efinopegdutide (MK-6024), an investigational GLP-1/glucagon receptor co-agonist, have been accepted for oral presentation at the European Association for the Study of the Liver (EASL) Annual Congress from June 21-24. Data to be shared include results from the Phase 2a clinical trial evaluating efinopegdutide in adult patients with nonalcoholic fatty liver disease (NAFLD).
Non-alcoholic Fatty Liver Disease (NAFLD) Companies Actively Working in the Therapeutic Market Include:
Afimmune, Alnylam Pharmaceuticals, Inc., AngioLab, AstraZeneca, BeiGene, Can Fite Biopharma, Chemomab Therapeutics, Cirius Therapeutics, CytoDyn, Inc., Dr. Falk Pharma GmbH, Eli Lilly and Company, Galectin Therapeutics, Galmed Pharmaceuticals, Hanmi Pharmaceutical, Hepagene Therapeutics, HighTide Biopharma, HK inno.N, Inventiva Pharma, Inventiva Pharma, Ionis Pharmaceuticals, Kowa Pharmaceutical, Lipocine, Inc., MediciNova, Metacrine, Inc., Mitsubishi Tanabe Pharma, NorthSea Therapeutics, Novartis, Novo Nordisk, NuSirt Biopharma, Oramed Pharmaceuticals, Pfizer, Poxel SA, Rivus Pharmaceuticals, Sagimet Biosciences, Sinew Pharma, Terns Pharmaceuticals, Viking Therapeutics, and others.
Emerging and Marketed Non-alcoholic Fatty Liver Disease (NAFLD) Drugs Covered in the Report Include:
Lanifibranor: Inventiva Pharma
Belapectin: Galectin Therapeutics
ZED 1227: Dr. Falk Pharma GmbH
TVB-2640: Sagimet Biosciences
ALS-L1023: AngioLab
MN-001: MediciNova
And Many Others
Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Non-alcoholic Fatty Liver Disease Companies Working in the Market @
Table of Content (TOC)
1. Report Introduction
2. Executive Summary
3. Non-alcoholic Fatty Liver Disease Treatment Patterns
4. Non-alcoholic Fatty Liver Disease – DelveInsight’s Analytical Perspective
5. Therapeutic Assessment
6. Non-alcoholic Fatty Liver Disease Late Stage Products (Phase-III)
7. Non-alcoholic Fatty Liver Disease Mid-Stage Products (Phase-II)
8. Non-alcoholic Fatty Liver Disease Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Non-alcoholic Fatty Liver Disease Discontinued Products
13. Non-alcoholic Fatty Liver Disease Product Profiles
14. Major Non-alcoholic Fatty Liver Disease Companies in the Market
15. Key Products in the Non-alcoholic Fatty Liver Disease Therapeutics Segment
16. Dormant and Discontinued Products
17. Non-alcoholic Fatty Liver Disease Unmet Needs
18. Non-alcoholic Fatty Liver Disease Future Perspectives
19. Non-alcoholic Fatty Liver Disease Analyst Review
20. Appendix
21. Report Methodology
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download Sample PDF to Explore the Key Offerings of the Report @
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Healthcare Reports By DelveInsight
Hernia Repair Devices Market
The Global Hernia Repair Devices Market was valued at USD 4.00 billion in 2021, growing at a CAGR of 5.08% during the forecast period from 2023 to 2028 to reach USD 5.38 billion by 2028. The rise in demand for Hernia Repair Devices is primarily attributed to the rising incidence of hernia, growing surgeries for hernia treatment, technological advancement in the product portfolio, and favorable reimbursement scenarios, among others.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Shruti ThakurEmail: Send EmailPhone: 09650213330Address:304 S. Jones Blvd #2432 City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/
